Getting Struck Twice: Acquisitions And Spinouts In Biotech

Biotech M&A deals are often driven by the buyer ' s interest in the lead asset in the biotech ' s portfolio. In order to capture the full value, spin-outs of the secondary assets following an acquisition can be solution. Several recent examples hare explored.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NYSE:BMY NASDAQ:BIVV NYSE:JNJ NYSE:AGN Source Type: news